Published in:
Open Access
01-02-2015 | Fertility Preservation
The role of menstrual cycle phase and AMH levels in breast cancer patients whose ovarian tissue was cryopreserved for oncofertility treatment
Authors:
Seido Takae, Yodo Sugishita, Nobuhito Yoshioka, Mariko Hoshina, Yuki Horage, Yorino Sato, Chie Nishijima, Kazuhiro Kawamura, Nao Suzuki
Published in:
Journal of Assisted Reproduction and Genetics
|
Issue 2/2015
Login to get access
Abstract
Purpose
To determine the factors that affect oocyte extraction efficiency when using the “combined procedure”. In the present “combined procedure” ovarian tissue cryopreservation and oocyte extraction from an isolated ovary, later used in In Vitro Maturation (IVM), are performed concurrently.
Methods
Data were analyzed retrospectively and obtained from the clinical records of 27 young breast cancer patients referred for fertility preservation.
Results
The patients’ mean age was 33.7 (±3.8) years, mean serum anti-Müllerian hormone (AMH) concentration was 3.5 (±2.1) ng/ml, and mean number of extracted oocytes was 8.3 (±6.1). The phase of menstruation (follicular or luteal) did not affect either the number of oocytes extracted (P = 0.99) nor oocyte survival or maturation rates. Likewise, the number of oocytes that could be extracted was not affected by the type of laparoscopic procedure (multiple-port or single-incision laparoscopy; P = 0.94) or the molecular subtype of breast cancer (either Luminal A or B; P = 0.52). Analysis revealed that the number of extracted oocytes was well-correlated with the patient’s AMH serum level and age (coefficient of correlation: 0.60 and −0.48, respectively).
Conclusion
We conclude that the outcome of the “combined procedure” primarily depends upon the patient’s serum AMH level and age. Importantly, the “combined procedure” may be used during any phase of the menstrual cycle to preserve the fertility of breast cancer patients.